Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients with Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes with the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial)

American Journal of Kidney Diseases

Volumn 66, Issue 3, 2015, Pages 450-458

  Schutte, Elise ^a   Lambers Heerspink, Hiddo J ^a   Lutgers, Helen L ^a   Bakker, Stephan J L ^a   Vart, Priya ^a   Wolffenbuttel, Bruce H R ^a   Umanath, Kausik ^b   Lewis, Julia B ^c   De Zeeuw, Dick ^a   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b HENRY FORD HOSPITAL   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

cardiovascular disease; diabetic nephropathy; end stage renal disease (ESRD); Index Words Diabetes mellitus; kidney disease progression; metabolic acidosis; mortality; risk predictor; serum bicarbonate; type 2 diabetes

Indexed keywords

BICARBONATE; CHLORIDE; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; IRBESARTAN; LOSARTAN; PHOSPHATE; POTASSIUM; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGE; ARTICLE; BICARBONATE BLOOD LEVEL; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; END STAGE RENAL DISEASE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; AGED; BLOOD; CHRONIC KIDNEY FAILURE; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; RISK FACTOR;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BICARBONATES; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TETRAZOLES;

EID: 84939568110     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.03.032     Document Type: Article

References (26)

1. National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease Am J Kidney Dis 49 2 suppl 2 2007 S12 S154
2. M. Dobre, W. Yang, J. Chen, and et al. Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) Study Am J Kidney Dis 62 4 2013 670 678
3. V. Menon, H. Tighiouart, N.S. Vaughn, and et al. Serum bicarbonate and long-term outcomes in CKD Am J Kidney Dis 56 5 2010 907 914
4. S.N. Shah, M. Abramowitz, T.H. Hostetter, and M.L. Melamed Serum bicarbonate levels and the progression of kidney disease: a cohort study Am J Kidney Dis 54 2 2009 270 277
5. C.P. Kovesdy, J.E. Anderson, and K. Kalantar-Zadeh Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD Nephrol Dial Transplant 24 4 2009 1232 1237
6. S.D. Navaneethan, J.D. Schold, S. Arrigain, and et al. Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease Clin J Am Soc Nephrol 6 10 2011 2395 2402
7. N. Goraya, and D.E. Wesson Does correction of metabolic acidosis slow chronic kidney disease progression? Curr Opin Nephrol Hypertens 22 2 2013 193 197
8. C.P. Kovesdy Metabolic acidosis and kidney disease: does bicarbonate therapy slow the progression of CKD? Nephrol Dial Transplant 27 8 2012 3056 3062
9. J.A. Kraut, and I. Kurtz Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment Am J Kidney Dis 45 6 2005 978 993
10. F. Caravaca, M. Arrobas, J.L. Pizarro, and J.F. Espárrago Metabolic acidosis in advanced renal failure: differences between diabetic and nondiabetic patients Am J Kidney Dis 33 5 1999 892 898
11. B.M. Brenner, M.E. Cooper, D. de Zeeuw, and et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 12 2001 861 869
12. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, and et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 12 2001 851 860
13. A.S. Levey, T. Greene, J.W. Kusek, and G.L. Beck MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract] J Am Soc Nephrol 11 2000 155A
14. A.F. Hayes Beyond Baron and Kenny: statistical mediation analysis in the new millennium Commun Monogr 76 4 2009 408 420
15. K.J. Preacher, and A.F. Hayes SPSS and SAS procedures for estimating indirect effects in simple mediation models Behav Res Methods Instrum Comput 36 4 2004 717 731
16. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 446 1999 496 509
17. R.A. DeFronzo Hyperkalemia and hyporeninemic hypoaldosteronism Kidney Int 17 1 1980 118 134
18. K. Kalantar-Zadeh, R. Mehrotra, D. Fouque, and J.D. Kopple Poor nutritional status and inflammation: metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure Semin Dial 17 6 2004 455 465
19. M.S. Devgun Delay in centrifugation and measurement of serum constituents in normal subjects Clin Physiol Biochem 7 3-4 1989 189 197
20. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease Kidney Int Suppl 3 1 2013
21. P. Susantitaphong, K. Sewaralthahab, E.M. Balk, B.L. Jaber, and N.E. Madias Short- and long-term effects of alkali therapy in chronic kidney disease: a systematic review Am J Nephrol 35 6 2012 540 547
22. M. Dobre, M. Rahman, and T.H. Hostetter Current status of bicarbonate in CKD J Am Soc Nephrol 26 3 2015 515 523
23. Di Iorio B. Correction of metabolic acidosis in end stage renal disease (ESRD). 2012. http://www.clinicaltrials.gov/ct2/show/NCT01640119?term=NCT01640119&rank=1. Accessed March 6, 2014.
24. Melamed ML. Alkali therapy in chronic kidney disease. http://www.clinicaltrials.gov/ct2/show/NCT01452412?term=NCT01452412&rank=1. Accessed March 6, 2014.
25. M. Gaggl, D. Cejka, M. Plischke, and et al. Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study) Trials 14 1 2013 196
26. Raphael KL. Investigations of the optimum serum bicarbonate level in renal disease. https://clinicaltrials.gov/ct2/show/NCT01574157?term=NCT01574157&rank=1. Accessed September 1, 2014.